Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease

European Journal of Neurology

Volumn 12, Issue 11, 2005, Pages 842-850

  Winge, Kristian ^a   Friberg, L ^a   Werdelin, L ^a   Nielsen, K K ^b   Stimpel, H ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Bladder dysfunction; Parkinson's disease; SPECT; Urodynamics

Indexed keywords

CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; ARTICLE; BASAL GANGLION; BLADDER FUNCTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; KIDNEY DISEASE; LIGAND BINDING; MALE; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; QUESTIONNAIRE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; URODYNAMICS;

ADULT; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 27744573696     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01087.x     Document Type: Article

References (43)

1. Abrams P, Cardozo L, Fall M et al. (2003). The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37-49.
2. Araki I, Kuno S (2000). Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429-433.
3. Araki I, Kitahara M, Oida T, Kuno S (2000). Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 164:1640-1643.
4. Aranda B, Cramer P (1993). Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 12:203-209.
5. Aranda B, Perrigot M, Mazieres L, Pierrot-Deseilligny E (1983). Bladder sphincter disorders in Parkinson's disease. Rev Neurol (Paris) 139:283-288.
6. Athwal BS, Berkley KJ, Hussain I et al. (2001). Brain responses to changes in bladder volume and urge to void in healthy men. Brain 124:369-377.
7. Blok BF, Willemsen AT, Holstege G (1997). A PET study on brain control of micturition in humans. Brain 120(Pt 1):111-121.
8. Booij J, Habraken JB, Bergmans P et al. (1998). Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39:1879-1884.
9. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho Jr RM, Ribeiro SC, de Carvalho DF (2003). Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 61:359-363.
10. Chai TC, Belville WD, McGuire EJ, Nyquist L (1993). Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 150(5 Pt 2):1710-1713.
11. Chandiramani VA, Palace J, Fowler CJ (1997). How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 80:100-104.
12. Christmas TJ, Kempster PA, Chapple CR et al. (1988). Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2:1451-1453.
13. Duchesne N, Soucy JP, Masson H, Chouinard S, Bedard MA (2002). Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clin Neuropharmacol 25:216-224.
14. Fitzmaurice H, Fowler CJ, Rickards D et al. (1985). Micturition disturbance in Parkinson's disease. Br J Urol 57:652-656.
15. Gelb DJ, Oliver E, Gilman S (1999). Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-39.
16. Gray R, Stern G, Malone-Lee J (1995). Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing 24:499-504. (see comments).
17. Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, Walter S (1991). A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 138:59-62.
18. Hansen BJ, Flyger H, Brasso K et al. (1995). Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 76:451-458.
19. Hansen F, Olsen L, Atan A, Jakobsen H, Nordling J (1997). Pressure-flow studies: an evaluation of within-testing reproducibility-validity of the measured parameters. Neurourol Urodyn 16:521-532.
20. Hansen BJ, Mortensen S, Mensink HJ et al. (1998). Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group. Br J Urol 81:36-41.
21. Hansen F, Olsen L, Atan A, Nordling J (1999). Pressure-flow studies: short-time repeatability. Neurourol Urodyn 18:205-214.
22. Hashimoto K, Oyama T, Sugiyama T, Park YC, Kurita T (2003). Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D(1) and D(2) receptors in rats. J Pharmacol Sci 92:143-148.
23. Hattori T, Yasuda K, Kita K, Hirayama K (1992). Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol 46:181-186.
24. Homma Y, Batista J, Bauer S et al. (2002). Urodynamics. In: Abrams P, Cardoz L, Khoury S, Wein A, eds. Incontinence. 2nd International Consultation on Incontinence, 2nd edn. Health Publication Ltd, Paris, pp. 317-372.
25. Kay L, Stigsby B, Brasso K, Mortensen SO, Munkgaard S (1999). Lower urinary tract symptoms - a population survey using the Danish Prostatic Symptom Score (DAN-PSS) questionnaire. Scand J Urol Nephrol 33:94-99.
26. Koskimaki J, Hakama M, Huhtala H, Tammela TL (1998). Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol 81:364-369.
27. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA (2000). Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:867-869.
28. Lemack GE, Dewey RB, Roehrborn CG, O'Suilleabhain PE, Zimmern PE (2000). Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 56:250-254.
29. Lepor H, Machi G (1993). Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 42:36-40.
30. Lokkegaard A, Werdelin LM, Friberg L (2002). Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 29:1623-1629.
31. Mattay VS, Tessitore A, Callicott JH et al. (2002). Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51:156-164.
32. Moller LA, Lose G, Jorgensen T (2000). The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet Gynecol Scand 79:298-305.
33. Nour S, Svarer C, Kristensen JK, Paulson OB, Law I (2000). Cerebral activation during micturition in normal men. Brain 123(Pt 4):781-789.
34. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ (1983). Neurourologic findings in Parkinson's disease. J Urol 129:80-83.
35. Pirker W, Asenbaum S, Hauk M et al. (2000). Imaging serotonin and dopamine transporters with 1231-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 41:36-44.
36. Sakakibara R, Shinotoh H, Uchiyama T et al. (2001a). Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 92:76-85.
37. Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T (2001b). SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 187:55-59.
38. Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger G, Madersbacher S (2001). A comparative cross-sectional study of lower urinary tract symptoms in both sexes. Eur Urol 40:213-219.
39. Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE (2001). Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 20:105-113.
40. Tissingh G, Bergmans P, Booij J et al. (1997). [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 24:1171-1174.
41. Winge K, Werdelin LM, Krøyer K, Stimpel H (2002). Bladder Dysfunction in young patients with Parkinson's Disease. Mov Disord 17(Suppl. 5):s218 Ref Type: Abstract.
42. Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O (1993). The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32:315-321.
43. Yoshimura N, Mizuta E, Yoshida O, Kuno S (1998). Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 286:228-233.